Johnston R E, Niesink F
J Int Med Res. 1979;7(3):187-93. doi: 10.1177/030006057900700305.
The long-term clinical effects of pipotiazine palmitate were tested in 206 men and women who were either not responding well to their previous neuroleptic therapy or who were negligent about pursuing protracted oral drug therapy. Of the 206 patients, 130 were suffering from some form of chronic schizophrenia; the remainder presented with depression, psychoneurotic or behavioural disorders. Pipotiazine palmitate, a long-acting depot neuroleptic, was given as a monthly intramuscular injection for up to 23 months. The average starting dose was 50 mg/injection and the average final dose was 65 mg/injection. These doses were somewhat lower than those usually reported in the literature, however all but a few patients received oral neuroleptics or antidepressants concomitantly. Psychiatric testing using the Brief Psychiatric Rating Scale revealed that significant improvement was achieved over time in all diagnostic groups represented. Individual as well as cumulative scores improved steadily for 6 momths at which time symptomatology was minimal in most patients. Pipotiazine palmitate was well tolerated, and only seven (3.4%) of the 206 patients had to interrupt therapy because of unwanted effects. The most frequent side-effects were extrapyramidal symptoms, particularly tremor and rigidity, yet these effects led to the discontinuation of therapy in only five patients.
对206名男性和女性患者进行了棕榈哌泊噻嗪的长期临床疗效测试，这些患者要么对之前的抗精神病药物治疗反应不佳，要么对长期口服药物治疗疏忽大意。在这206名患者中，130名患有某种形式的慢性精神分裂症；其余患者表现为抑郁症、精神神经症或行为障碍。棕榈哌泊噻嗪是一种长效长效抗精神病药物，每月进行一次肌肉注射，持续长达23个月。平均起始剂量为50毫克/次注射，平均最终剂量为65毫克/次注射。这些剂量略低于文献中通常报道的剂量，然而除少数患者外，所有患者均同时接受口服抗精神病药物或抗抑郁药物治疗。使用简明精神病评定量表进行的精神病学测试显示，随着时间的推移，所有代表的诊断组均取得了显著改善。个体得分和累积得分在6个月内稳步提高，此时大多数患者的症状最轻。棕榈哌泊噻嗪耐受性良好，206名患者中只有7名（3.4%）因不良反应而不得不中断治疗。最常见的副作用是锥体外系症状，尤其是震颤和僵硬，但这些影响仅导致5名患者停止治疗。
